CymaBay Therapeutics

CymaBay Therapeutics

Pharmaceutical Manufacturing

Newark, California 13,172 followers

Dedicated to improving the lives of patients with liver diseases

About us

We are a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need. Seladelpar is a potent, selective, orally active PPARδ agonist in development for the treatment of patients with the autoimmune liver disease, primary biliary cholangitis (PBC). Our pipeline also includes additional investigational products and lead candidates for liver and other chronic diseases.

Industry
Pharmaceutical Manufacturing
Company size
11-50 employees
Headquarters
Newark, California
Type
Public Company

Locations

  • Primary

    7575 Gateway Blvd

    Suite 110

    Newark, California 94560, US

    Get directions

Employees at CymaBay Therapeutics

Updates

Affiliated pages

Similar pages

Browse jobs

Funding

CymaBay Therapeutics 16 total rounds

Last Round

Post IPO equity

US$ 258.7M

See more info on crunchbase